Long-term intravesical oxybutynin chloride therapy in children with myelodysplasia
Long-term intravesical oxybutynin chloride therapy in children with myelodysplasia
复制标题
DOI：
10.1016/s0022-5347(01)65629-5
复制
发表时间：
1996-10-01
影响因子：
6.6
通讯作者：
Perlmutter, AD
中科院分区：
文献类型：
--
作者：
Painter, KA;Vates, TS;Perlmutter, AD
目的：我们评估长期膀胱内氯氧布宁治疗不能耐受口服抗胆碱能药物的骨髓发育不良儿童神经源性膀胱功能障碍的临床应用。材料和方法：我们回顾性地回顾了所有推荐经膀胱使用氯氧布宁治疗的患者的记录。总共招募了12名1至17岁的女孩和18名男孩进行研究。每天输注2次氯奥昔布宁（5mg），并将预处理膀胱图与随访尿动力学研究进行比较。治疗时间为2 ~ 26个月（平均13个月，中位数12个月）。结果：平均总容量正负标准差从209 +/- 103增加到282 +/- 148英里（p < 0.01），平均安全容量从157 +/- 105增加到234 +/- 147英里（p < 0.01），平均年龄调整安全容量从76 +/- 36%增加到115 +/- 62%。在29例失禁患者中，3例（10%）实现了失禁，19例（65%）报告减少了卫生巾的使用。所有患者均未出现与膀胱内治疗相关的全身副作用。结论：我们认为，对于口服治疗失败的骨髓增生患者，膀胱内注射氯氧布宁是一种可行的治疗选择。
Purpose: We evaluated the clinical use of long-term intravesical oxybutynin chloride in the treatment of neurogenic bladder dysfunction in children with myelodysplasia who could not tolerate oral anticholinergics.Materials and Methods: We retrospectively reviewed the records of all patients recommended for intravesical oxybutynin chloride therapy. A total of 12 girls and 18 boys 1 to 17 years old was recruited for study. Oxybutynin chloride (5 mg.) was instilled 2 times daily and pretreatment cystograms were compared to followup urodynamic studies. Duration of therapy was 2 to 26 months (mean 13, median 12).Results: Mean total capacity plus or minus standard deviation increased from 209 +/- 103 to 282 +/- 148 mi. (p < 0.01), mean safe capacity increased from 157 +/- 105 to 234 +/- 147 mi. (p < 0.01) and mean age adjusted safe capacity increased from 76 +/- 36 to 115 +/- 62%. Of the 29 patients who were incontinent 3 (10%) achieved continence and 19 (65%) reported a decreased use of sanitary pads. None of the patients had systemic side effects related to intravesical treatment.Conclusions: We believe that intravesical oxybutynin chloride is a viable treatment option for patients with myelodysplasia in whom oral therapy fails.